BioS+
IntoCell, 3 potentials of development of antibody replacement ADC platform
바이오스펙테이터 Kim Sungmin 기자
‘Into Cell, Into practice’, the company logo means that we can actualize many things by injecting cancer attacking materials into a cell. Our ‘IntoCell Drug Conjugate (IDC)’ platform is a new concept that existing anticancer drug market does not have.
Tae-gyo Park, CEO of IntoCell Inc., at a recent meeting with Biospectator, introduced a new self-developed technology platform “that others have not yet done”. IntoCell is a company founded by key players of Legochembio R&D members, whom took major roles in research of antibody-drug conjugates (ADC) and linkers. Started in April 2015, IntoCell has been acknowledged for its experience and potential technology in research fields. As the brand awareness continued to rise, Intocell received investment of 6 billion won from five venture capital companies, and they are accelerating in research and development with the sufficient funds.
ADC is an antibody-linker-drug structure that uses antibodies to deliver drugs to specifically targeted cancer cells and eventually eliminate them. Because of its specific mechanism of delivering drugs to cancer cells, ADC was expected to be superior in drug efficacy and toxicity level than the other low-molecular drugs. But, for various causes, its therapeutic window was not wider than expected. However, IntoCell is proposing a new methodology.
